跳至主要内容
临床试验/CTRI/2024/07/069964
CTRI/2024/07/069964尚未招募3 期

Comparative therapeutic evaluation of oral tofacitinib versus methotrexate in moderate to severe chronic plaque Psoriasis - A hospital based randomized control trial

Dr Rohit Kumar Singh1 个研究点 分布在 1 个国家目标入组 112 人开始时间: 2024年7月15日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
112
试验地点
1
主要终点
Clinical response as indicated by PASI75 score after 16 weeks of treatment

研究概览

简要总结

We are conducting this randomized controlled trial in the dept. of dermatology and venerology , AIIMS gorakhpur , comparing the safety and efficacy of oral tofacitinib versus oral methotrexate in patients of moderate to severe chronic plaque psoriasis over the course of 16 weeks.

POPULATION/ PARTICIPANTS: Patients visiting dermatology OPD with diagnosed case of chronic plaque psoriasis diagnosed clinically with age between 18-65 years, satisfying the inclusion criteria, and willing to participate in the study.

INCLUSION CRITERIA: patients fulfilling the following criteria will be included in the study

1.      Patients between the age group of 18 – 65 yrs.

2.      BSA > 5% and PASI score > 3

3.      Patients with well controlled diabetes, hypertension and thyroid disorder.

EXCLUSION CRITERIA: patients fulfilling the following criteria will be excluded from the study

1.      Patients not consenting to the study.

2.      Patient with deranged biochemical profile.

3.      Pregnant and lactating women.

 PRIMARY END POINT :

1. Comparison of PASI75 between the two study groups after 16 weeks of treatment.

SECONDARY ENDPOINT :

1. Mean improvement in Body Surface Area (BSA) involvement by the end of 16 weeks.

2. Achievement of PASI 90.

3. Improvement in Severity of Nail Psoriasis Score (SNAPS)

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Outcome Assessor Blinded

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • 1.patients of 18 to 65 years of age 2.BSA more than 5% and PASI more than 3 3.Patients with well controlled diabetes, hypertension and thyroid disorder.

排除标准

  • Patients not consenting to the study.
  • Patient with deranged biochemical profile.
  • Pregnant and lactating women.

结局指标

主要结局

Clinical response as indicated by PASI75 score after 16 weeks of treatment

时间窗: 16 weeks

次要结局

  • 1. Assessing The Dermatology Life Quality Index (DLQI) before , during and after the completion of 16 months.(2. Assessing the changes in Severity of Nail Psoriasis Score (SNAPS) after completion of 16 weeks.)

研究者

发起方
Dr Rohit Kumar Singh
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Rohit Kumar Singh

Dept. of dermatology and venerology , All india institute of medical sciences, gorakhpur

研究点 (1)

Loading locations...

相似试验